Skip to main content
20th International Myeloma Workshop Main banner
Back

    Paul G. Richardson, MD

    Clinical Program Leader and Director of Clinical Research
    Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Boston, Massachusetts, United States

    • Dr Richardson led the development of several first-generation novel drugs for the treatment of multiple myeloma, including bortezomib, lenalidomide, and pomalidomide. He also has experience working on next-generation novel drugs, including panobinostat, and second-generation proteasome inhibitors, such as ixazomib. His recent clinical innovations include the development of breakthrough monoclonal antibodies, elotuzumab and daratumumab, as well as isatuximab and the BCMA-targeting antibody-drug conjugate, belantamab mafodotin. Dr Richardson is the principal investigator for the DREAMM-5 clinical trial and participated in DREAMM 1 and 2. Additionally, he has contributed to the development of melflufen and the first-in-class small molecule inhibitor selinexor, as well as to the first-in-human studies of cereblon E3 ligase modulators (CELMoDs) for the treatment of RRMM, including mezigdomide
    • Dr Richardson’s prolific publication experience includes authoring and coauthoring more than 460 original articles and 340 review articles, book chapters, and editorials in peer-reviewed journals. Dr Richardson holds positions on the Editorial Boards of leading journals, including the British Journal of Haematology and Haematologica. He is prior Chairman of the Multiple Myeloma Research Consortium and the Clinical Trials Core. He has also served as a member of the ASCO Hematologic Malignancies Subcommittee and the ASCO Internet Cancer Information Committee. He was appointed Chair of the Alliance Myeloma Committee and completed his 10-year tenure in 2021
    • Current directions and research priorities include developing approaches as part of individual/remission therapies such as RVD and Dara with the goal of tailoring treatment to optimize patient outcome, exemplified by the DETERMINATION study and its successor trials such as GRIFFIN

    Presentation(s):